Bangladesh is seeking deeper health-sector cooperation with China and other Asian partners, with pharmaceuticals and health technology placed among four priority areas for future collaboration. The priorities also include artificial intelligence and digital health, healthy ageing, and vaccines and health security. The focus is especially relevant for Bangladesh’s pharmaceutical industry, which already exports medicines to nearly 160 countries and has built a strong base in generic drug manufacturing. The next stage of growth can come from moving further into active pharmaceutical ingredients, advanced research, technology transfer and more sophisticated health products. Bangladesh has expressed interest in improving access for locally produced medicines to the Chinese market while also developing partnerships in API production, research and smart health infrastructure. API capability is important because it can reduce dependence on imported pharmaceutical ingredients and allow local manufacturers to capture more value within the production chain. Technology transfer and joint research can also help companies strengthen quality systems, introduce new products and meet demanding international standards. The cooperation agenda extends beyond traditional pharmaceuticals. Bangladesh has identified opportunities in AI-supported diagnosis, treatment, medical education, precision medicine, robotic surgery, chronic-disease management and remote patient monitoring. These areas create possibilities for collaboration between pharmaceutical companies, hospitals, research institutions and technology businesses. Vaccine research and production is another priority, along with more stable supply chains. Developing stronger vaccine capability could support health security while adding another high-value area to Bangladesh’s life-sciences sector. The growing elderly population across Asia also creates demand for rehabilitation services, assistive technologies and age-friendly healthcare, providing further space for innovation. Bangladesh’s main advantage is that it already has a large domestic pharmaceutical market, experienced manufacturers and an export record that can support the move toward more advanced products. International partnerships can add scientific knowledge, equipment, research links and market access. The key will be turning cooperation discussions into practical projects with clear standards and commercial value. Stronger university-industry research links and investment in skilled scientists will also be important. If these partnerships develop effectively, Bangladesh can build on its existing pharmaceutical success and move toward a more research-driven, technology-intensive health industry with stronger export potential and deeper regional connections.
